A patented mechanical system designed to obtain tissue-specific autologous micrografts through controlled mechanical disaggregation.
Rigenera® Technology is a patented mechanical system designed to obtain tissue-specific autologous micrografts through controlled mechanical disaggregation.
The process generates an injectable suspension of 80 µm micrografts (AMT), preserving high cell and biological component viability without enzymatic digestion or cell expansion.
Supported by 80+ peer-reviewed scientific publications, the AMT suspension is used across multiple regenerative medicine applications.
Rigenera® Technology operates through the synergy of three core elements.
Sterile class IIa disposable device containing calibrated microblades designed to mechanically disaggregate tissue samples.
Motorized device providing controlled rotation to ensure standardized micrograft generation.
Transfers rotational mechanical energy from the N4SA Machine to the Rigeneracons.
Auricular cartilage contains a perichondrium layer rich in mesenchymal progenitor cells and chondroblasts, which play a key role in cartilage regeneration and tissue homeostasis.
Chondroprogenitor Cells
Chondrocytes
Extracellular Matrix Components
Signaling Factors (Cytokines, Growth Factors)
Chondrogenic Genes And Proteins
Modulation of inflammatory signaling
Support of extracellular matrix homeostasis
Activation of endogenous regenerative pathways
This environment supports cartilage function and contributes to reduction of pain and stiffness in degenerative joint conditions.
Download Scientific Brochure